[go: up one dir, main page]

WO2010072327A3 - Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch - Google Patents

Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch Download PDF

Info

Publication number
WO2010072327A3
WO2010072327A3 PCT/EP2009/008768 EP2009008768W WO2010072327A3 WO 2010072327 A3 WO2010072327 A3 WO 2010072327A3 EP 2009008768 W EP2009008768 W EP 2009008768W WO 2010072327 A3 WO2010072327 A3 WO 2010072327A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
treated
diseases
zaap
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/008768
Other languages
English (en)
French (fr)
Other versions
WO2010072327A2 (de
Inventor
Khaled Al Zoubi
Karen Depta
Marwan Al Falah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KAMAMED GmbH
Original Assignee
KAMAMED GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KAMAMED GmbH filed Critical KAMAMED GmbH
Publication of WO2010072327A2 publication Critical patent/WO2010072327A2/de
Publication of WO2010072327A3 publication Critical patent/WO2010072327A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft Peptide, die z.B. aus Kamelmilch isolierbar sind, und als Wirkstoff in pharmazeutischen Zusammensetzungen verwendet werden können, insbesondere zur Verwendung bei medizinischen Indikationen, die durch Hemmung der humanen DPP4, CD26, zAAP und/oder DPP8 und/oder DPP9 therapiert werden können, insbesondere Diabetes mellitus Typ 2, Fettleibigkeit und/oder Herz-Kreislauf-Erkrankungen, sowie Erkrankungen, die durch T-Zellen verursacht sind, bzw. die durch Beeinflussung von T-Zellen behandelbar sind, und insbesondere durch Hemmung von DPP4 bzw. dessen zellgebundener Form CD26 und/oder APN und/oder zAAP behandelbar sind, z.B. Autoimmunerkrankungen. Weiterhin betrifft die Erfindung pharmazeutische Zusammensetzungen zur Verwendung bei neuronalen Erkrankungen, die durch Hemmung der DPP4 bzw. von CD26 und/oder Hemmung von APN und/oder zAAP und/oder bei neuronalen Erkrankungen, durch Hemmung der DPP 8 und/oder DPP9 behandelbar sind.
PCT/EP2009/008768 2008-12-16 2009-12-08 Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch Ceased WO2010072327A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008062136A DE102008062136B4 (de) 2008-12-16 2008-12-16 Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
DE102008062136.6 2008-12-16

Publications (2)

Publication Number Publication Date
WO2010072327A2 WO2010072327A2 (de) 2010-07-01
WO2010072327A3 true WO2010072327A3 (de) 2010-12-29

Family

ID=42168685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/008768 Ceased WO2010072327A2 (de) 2008-12-16 2009-12-08 Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch

Country Status (2)

Country Link
DE (1) DE102008062136B4 (de)
WO (1) WO2010072327A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018566A1 (en) 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
CN105833256A (zh) * 2012-03-09 2016-08-10 森永乳业株式会社 二肽基肽酶iv抑制剂
JP6517732B2 (ja) * 2016-06-01 2019-05-22 株式会社ニッピ Ｄｐｐ−４阻害剤、血糖値上昇抑制剤およびｄｐｐ−４阻害用食品
US10336817B2 (en) 2016-10-14 2019-07-02 Sultan Qaboos University Therapeutic composition of camel milk
CN109645123A (zh) * 2018-11-06 2019-04-19 新疆金驼投资股份有限公司 一种具有调节脂代谢功能的益生菌jt6骆驼乳粉组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003729A1 (de) * 1998-07-15 2000-01-27 Ursapharm Arzneimittel Gmbh Verwendung von bromelainproteasen zur hemmung der blutgerinnung
WO2000014254A2 (en) * 1998-09-02 2000-03-16 Cortecs (Uk) Limited Component of bromelain
WO2006068480A2 (en) * 2004-12-23 2006-06-29 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
JP2007039424A (ja) * 2005-07-01 2007-02-15 Snow Brand Milk Prod Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433623A1 (de) 1998-02-02 2012-03-28 Trustees Of Tufts College Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
DE102004040452A1 (de) * 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
US7219998B2 (en) * 2004-12-16 2007-05-22 Bausch And Lomb Incorporated Dot radial ringed placido

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003729A1 (de) * 1998-07-15 2000-01-27 Ursapharm Arzneimittel Gmbh Verwendung von bromelainproteasen zur hemmung der blutgerinnung
WO2000014254A2 (en) * 1998-09-02 2000-03-16 Cortecs (Uk) Limited Component of bromelain
WO2006068480A2 (en) * 2004-12-23 2006-06-29 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
JP2007039424A (ja) * 2005-07-01 2007-02-15 Snow Brand Milk Prod Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200722, Derwent World Patents Index; AN 2007-214433, XP002597235, SNOW BRAND MILK PROD CO LTD: "Dipeptidyl peptidase IV inhibitor useful for treating obesity, non-insulin dependent diabetes mellitus and hyperglycemia, comprises water-soluble fraction of cheese as active ingredient" *
KOHMURA M ET AL: "INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME BY SYNTHETIC PEPTIDES OF HUMAN BETA-CASEIN", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, JAPAN SOC. FOR BIOSCIENCE, BIOTECHNOLOGY AND AGROCHEM, TOKYO, JP, vol. 53, no. 8, 1 August 1989 (1989-08-01), pages 2107 - 2114, XP001105965, ISSN: 0002-1369 *

Also Published As

Publication number Publication date
DE102008062136B4 (de) 2012-05-03
DE102008062136A1 (de) 2010-06-17
WO2010072327A2 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
GEP20125565B (en) Lactam compounds and their pharmaceutical use
IL184554A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
WO2011059763A3 (en) Dimeric smac mimetics
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
MX2009004362A (es) Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk.
WO2011150156A3 (en) Heteroaryl compounds and methods of use thereof
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2007007173A3 (en) Human anti-madcam antibodies
WO2011011797A3 (en) Cytokine compositions and methods of use thereof
WO2010085700A3 (en) Treatment for obesity
WO2008087186A3 (en) Peptides for use in the treatment of obesity
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2010072327A3 (de) Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
WO2008087188A3 (en) Peptides for use in the treatment of obesity
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: FESTSTELLUNG EINES RECHTSVERLUSTS NACH REGEL 112(1) EPUE (EPA FORM 1205A VOM 31/08/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09767985

Country of ref document: EP

Kind code of ref document: A2